<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02116127</url>
  </required_header>
  <id_info>
    <org_study_id>NI14-020</org_study_id>
    <nct_id>NCT02116127</nct_id>
  </id_info>
  <brief_title>Transcranial Direct Current Stimulation (tDCS) for Depression in Pregnancy: A Pilot Study</brief_title>
  <official_title>Transcranial Direct Current Stimulation (tDCS) for Depression in Pregnancy: A Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Women's College Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Mount Sinai Hospital, Canada</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Centre for Addiction and Mental Health</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Women's College Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this pilot study is to examine the feasibility of conducting a multi-site
      double-blind randomized controlled trial whose aim will be to evaluate the effectiveness of
      transcranial direct current stimulation (tDCS) for treatment in pregnant women with moderate
      to severe major depression.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Major depression is a serious condition that affects up to 10% of pregnant women, and has
      serious impact on the developing fetus. However current treatments are less than ideal for
      women with moderate to severe depression. Psychotherapy alone is either ineffective, or takes
      months to improve symptoms, leaving the fetus susceptible to depression during that time.
      Antidepressant medication is effective, but there are high refusal rates of standard
      pharmacological treatment because of fears about medication exposure. The highly negative
      impacts of depression in pregnancy on the developing fetus and child illustrate the need for
      evaluation of timely and innovative treatments.

      Transcranial direct current stimulation (tDCS) is a non-drug treatment for depression where
      the dorsolateral prefrontal cortex, a part of the brain that functions abnormally when an
      individual is depressed, can be directly stimulated without impacting any other parts of the
      body or brain. As such, it is an ideal treatment for pregnant women who do not want to expose
      their fetus to the impact of medication treatment for depression. It has been shown to be
      effective in depression among non-pregnant adults and improvement is seen rapidly with a
      3-week treatment course, almost 3 times faster than standard psychological treatment. There
      are no known serious adverse effects and no theoretical risk to a fetus.

      This research study will measure the feasibility, acceptability and compliance of the tDCS as
      a treatment option for depression in pregnancy. In addition, the study will investigate the
      effect of tDCS on reducing depressive symptoms immediately post-treatment among women who
      have moderate to severe depression in pregnancy.

      In this multi-centre, pilot randomized controlled trial, adult women with moderate to severe
      depression in pregnancy will be recruited from one hospital obstetrical group and two
      specialty perinatal mental health clinics over the course of 1 year. Women will have been
      offered to start or continue SSRI (Selective Serotonin Reuptake Inhibitors) or SNRI
      (Selective Serotonin-Norepinephrine Reuptake Inhibitors)medication but declined use. All
      participants will continue to receive clinical care from their respective clinical programs
      during the trial. Although this care may include psychotherapeutic intervention that is
      initiated prior to completion of the active tDCS treatment phase (if clinic psychotherapy
      waitlist is short), we would not expect to see improvement within the first 3 weeks of
      psychotherapeutic treatment. As such, this is an ideal opportunity to evaluate the efficacy
      of a new treatment, without depriving women of non-pharmacological standard care.

      Following informed consent procedures, participants will be randomized to tDCS or a
      sham-control condition (1:1) with on-site treatments 5 days per week over 3 weeks in 30
      minute sessions. The intervention is active 2mA transcranial direct current stimulation
      (tDCS). Direct current will be transferred with a pair of saline soaked sponge electrodes
      (contact area 5 x 7cm), and delivered by a specially developed, battery driven constant
      current stimulator. The electrodes will be placed over F3 and F4 according to the
      international system for EEG (Electroencephalogram) placement. Sham stimulation will be
      administered using the same stimulation parameters and at the site of active treatment, but
      the current will be turned off after 30 seconds.

      Women will be interviewed at baseline and then followed during treatment, every four weeks
      until delivery, and at four and twelve weeks postpartum to allow for measurement of
      depressive symptoms, pregnancy, delivery, neonatal and infant outcomes. Although baseline and
      treatment interviews will be conducted in person, post-treatment and post-delivery interviews
      will be offered in person or over the telephone, according to participant preference.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2014</start_date>
  <completion_date type="Actual">July 2017</completion_date>
  <primary_completion_date type="Actual">July 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants recruited over 1 year</measure>
    <time_frame>Up to one year from when the study starts enrolling participants</time_frame>
    <description>Feasibility</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Montgomery Asberg Depression Rating Scale</measure>
    <time_frame>End of week 1</time_frame>
    <description>Efficacy - Depression Symptom Measurement</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Edinburgh Postnatal Depression Scale</measure>
    <time_frame>End of Week 1</time_frame>
    <description>Efficacy - Depression Symptom Measurement</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pregnancy Experience Scale</measure>
    <time_frame>End of Week 1</time_frame>
    <description>Efficacy - Secondary Symptom Measurement</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>State-Trait Anxiety Inventory</measure>
    <time_frame>End of week 1</time_frame>
    <description>Efficacy - Secondary Symptom Measurement</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Itemized neonatal health outcomes questionnaire</measure>
    <time_frame>4 weeks postpartum</time_frame>
    <description>Neonatal outcome (safety)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Itemized neonatal health outcomes questionnaire</measure>
    <time_frame>12 weeks postpartum</time_frame>
    <description>Neonatal Outcome (safety)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bates Infant Characteristics Questionnaire</measure>
    <time_frame>12 weeks postpartum</time_frame>
    <description>Infant outcome (temperament)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ages and Stages Questionnaire</measure>
    <time_frame>12 weeks postpartum</time_frame>
    <description>Infant outcome (development)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toronto Side Effects Scale</measure>
    <time_frame>End of Week 1</time_frame>
    <description>Acceptability - side effects</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toronto Side Effects Scale</measure>
    <time_frame>End of week 2</time_frame>
    <description>Acceptability - side effects</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toronto Side Effects Scale</measure>
    <time_frame>End of intervention phase (end of week 3)</time_frame>
    <description>Acceptability - side effects</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Itemized treatment acceptability questionnaire</measure>
    <time_frame>End of intervention phase (end of week 3)</time_frame>
    <description>Acceptability - barriers and facilitators of attending appointments</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pregnancy Complications Itemized Questionnaire</measure>
    <time_frame>End of week 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pregnancy Complications Itemized Questionnaire</measure>
    <time_frame>End of week 2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pregnancy Complications Itemized Questionnaire</measure>
    <time_frame>End of intervention phase (end of week 3)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pregnancy Complications Itemized Questionnaire</measure>
    <time_frame>Every 4 weeks until delivery of baby (up to 26 weeks from initial randomization)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pregnancy Complications Itemized Questionnaire</measure>
    <time_frame>4 weeks postpartum</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of follow-up data collection</measure>
    <time_frame>12 weeks postpartum</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Completion of all 15 treatment sessions</measure>
    <time_frame>End of intervention phase (end of week 3)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment allocation questionnaire</measure>
    <time_frame>End of week 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment allocation questionnaire</measure>
    <time_frame>End of intervention phase (end of week 3)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Montgomery Asberg Depression Rating Scale</measure>
    <time_frame>End of week 2</time_frame>
    <description>Efficacy - Depression Symptom Measurement</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Edinburgh Postnatal Depression Scale</measure>
    <time_frame>End of Week 2</time_frame>
    <description>Efficacy - Depression Symptom Measurement</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Montgomery Asberg Depression Rating Scale</measure>
    <time_frame>End of intervention phase (End of week 3)</time_frame>
    <description>Efficacy - Depression Symptom Measurement</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Montgomery Asberg Depression Rating Scale</measure>
    <time_frame>Every 4 weeks until delivery (i.e. up to 26 weeks from initial randomization)</time_frame>
    <description>Efficacy - Depression Symptom Measurement</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Montgomery Asberg Depression Rating Scale</measure>
    <time_frame>4 weeks postpartum</time_frame>
    <description>Efficacy - Depression Symptom Measurement</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Montgomery Asberg Depression Rating Scale</measure>
    <time_frame>12 weeks postpartum</time_frame>
    <description>Efficacy - Depression Symptom Measurement</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Edinburgh Postnatal Depression Scale</measure>
    <time_frame>End of intervention phase (Week 3)</time_frame>
    <description>Efficacy - Depression Symptom Measurement</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Edinburgh Postnatal Depression Scale</measure>
    <time_frame>Every 4 weeks until delivery (i.e. up to 26 weeks from initial randomization)</time_frame>
    <description>Efficacy - Depression Symptom Measurement</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Edinburgh Postnatal Depression Scale</measure>
    <time_frame>4 weeks postpartum</time_frame>
    <description>Efficacy - Depression Symptom Measurement</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Edinburgh Postnatal Depression Scale</measure>
    <time_frame>12 weeks postpartum</time_frame>
    <description>Efficacy - Depression Symptom Measurement</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pregnancy Experience Scale</measure>
    <time_frame>End of Week 2</time_frame>
    <description>Efficacy - Secondary Symptom Measurement</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pregnancy Experience Scale</measure>
    <time_frame>End of intervention phase (Week 3)</time_frame>
    <description>Efficacy - Secondary Symptom Measurement</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pregnancy Experience Scale</measure>
    <time_frame>Every 4 weeks until delivery (i.e. up to 26 weeks from initial randomization)</time_frame>
    <description>Efficacy - Secondary Symptom Measurement</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>State-Trait Anxiety Inventory</measure>
    <time_frame>End of week 2</time_frame>
    <description>Efficacy - Secondary Symptom Measurement</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>State-Trait Anxiety Inventory</measure>
    <time_frame>End of intervention phase (end of week 3)</time_frame>
    <description>Efficacy - Secondary Symptom Measurement</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>State-Trait Anxiety Inventory</measure>
    <time_frame>Every 4 weeks until delivery (i.e. up to 26 weeks from initial randomization)</time_frame>
    <description>Efficacy - Secondary Symptom Measurement</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>State-Trait Anxiety Inventory</measure>
    <time_frame>4 weeks postpartum</time_frame>
    <description>Efficacy - Secondary Symptom Measurement</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>State-Trait Anxiety Inventory</measure>
    <time_frame>12 weeks postpartum</time_frame>
    <description>Efficacy - Secondary Symptom Measurement</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Depression</condition>
  <condition>Pregnancy</condition>
  <arm_group>
    <arm_group_label>Active tDCS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The intervention is active 2mA transcranial direct current stimulation (tDCS). Direct current will be transferred with a pair of saline soaked sponge electrodes (contact area 5 x 7cm), and delivered for 30 minutes. The electrodes will be placed over F3 and F4 according to the 10-20 international system for EEG placement.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sham tDCS</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>The sham intervention is transcranial direct current stimulation (tDCS). 2mA of direct current will be transferred with a pair of saline soaked sponge electrodes (contact area 5 x 7cm), and the current will be turned off after 54 seconds.The electrodes will be placed over F3 and F4 according to the 10-20 international system for EEG placement.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Active tDCS</intervention_name>
    <description>The intervention is active 2mA transcranial direct current stimulation (tDCS). Direct current will be transferred with a pair of saline soaked sponge electrodes (contact area 5 x 7cm), and delivered for 30 minutes. The electrodes will be placed over F3 and F4 according to the 10-20 international system for EEG placement.</description>
    <arm_group_label>Active tDCS</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Sham tDCS</intervention_name>
    <description>The sham intervention is transcranial direct current stimulation (tDCS). 2mA of direct current will be transferred with a pair of saline soaked sponge electrodes (contact area 5 x 7cm), and the current will be turned off after 54 seconds.The electrodes will be placed over F3 and F4 according to the 10-20 international system for EEG placement.</description>
    <arm_group_label>Sham tDCS</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Pregnant women aged &gt; 18 years

          2. &gt;12 weeks gestation at enrollment

          3. 32 or fewer weeks gestation at first treatment visit (to increase likelihood of all
             treatment occurring during pregnancy)

          4. Diagnosis of Major Depressive Disorder and in a Moderate-severe major depressive
             episode without psychotic features (as confirmed by the Mini-International
             Neuropsychiatric Interview, MINI ).

          5. Safe for outpatient psychiatric treatment (as assessed by Study PI).

          6. Offered, but declined to use an anti-depressant medication

          7. Capable to consent to treatment

          8. Able to understand study explanations and have questionnaires administered in English

        Exclusion Criteria:

          1. DSM-V history of alcohol and/or substance use or dependence in the previous 6 months

          2. Concomitant major and unstable medical or neurologic illness or history of seizure

          3. Currently taking carbamazepine (which may interfere with the effects of anodal tDCS),

          4. Major complications and/or a known fetal anomaly in the current pregnancy as
             determined by the investigator team

          5. Planning to leave Toronto prior to delivery in the current pregnancy.

          6. Metal implant(s) in cranium

          7. Electrical implant(s) in body

          8. Currently taking benzodiazepines daily (Intermittent PRN use of low-dose Lorazepam
             allowed)

          9. Non-intact skin on scalp areas where stimulation electrodes will be placed

         10. History of very preterm delivery in previous pregnancy (&lt; 32 weeks gestation)
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Simone N Vigod, MD, MSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Women's College Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Daniel M Blumberger, MD, MSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre for Addiction and Mental Health</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mount Sinai Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 1X5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Women's College Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5S 1B2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <reference>
    <citation>Bates JE, Freeland CA, Lounsbury ML. Measurement of infant difficultness. Child Dev. 1979 Sep;50(3):794-803.</citation>
    <PMID>498854</PMID>
  </reference>
  <reference>
    <citation>Steer RA, Scholl TO, Hediger ML, Fischer RL. Self-reported depression and negative pregnancy outcomes. J Clin Epidemiol. 1992 Oct;45(10):1093-9.</citation>
    <PMID>1474405</PMID>
  </reference>
  <reference>
    <citation>Murray L. The impact of postnatal depression on infant development. J Child Psychol Psychiatry. 1992 Mar;33(3):543-61.</citation>
    <PMID>1577898</PMID>
  </reference>
  <reference>
    <citation>Zuckerman B, Bauchner H, Parker S, Cabral H. Maternal depressive symptoms during pregnancy, and newborn irritability. J Dev Behav Pediatr. 1990 Aug;11(4):190-4.</citation>
    <PMID>2212032</PMID>
  </reference>
  <reference>
    <citation>Williams JB. A structured interview guide for the Hamilton Depression Rating Scale. Arch Gen Psychiatry. 1988 Aug;45(8):742-7.</citation>
    <PMID>3395203</PMID>
  </reference>
  <reference>
    <citation>Sandman CA, Wadhwa PD, Dunkel-Schetter C, Chicz-DeMet A, Belman J, Porto M, Murata Y, Garite TJ, Crinella FM. Psychobiological influences of stress and HPA regulation on the human fetus and infant birth outcomes. Ann N Y Acad Sci. 1994 Oct 31;739:198-210.</citation>
    <PMID>7832474</PMID>
  </reference>
  <reference>
    <citation>Pastuszak A, Schick-Boschetto B, Zuber C, Feldkamp M, Pinelli M, Sihn S, Donnenfeld A, McCormack M, Leen-Mitchell M, Woodland C, et al. Pregnancy outcome following first-trimester exposure to fluoxetine (Prozac). JAMA. 1993 May 5;269(17):2246-8.</citation>
    <PMID>8474204</PMID>
  </reference>
  <reference>
    <citation>Orr ST, Miller CA. Maternal depressive symptoms and the risk of poor pregnancy outcome. Review of the literature and preliminary findings. Epidemiol Rev. 1995;17(1):165-71. Review.</citation>
    <PMID>8521934</PMID>
  </reference>
  <reference>
    <citation>Chambers CD, Johnson KA, Dick LM, Felix RJ, Jones KL. Birth outcomes in pregnant women taking fluoxetine. N Engl J Med. 1996 Oct 3;335(14):1010-5.</citation>
    <PMID>8793924</PMID>
  </reference>
  <reference>
    <citation>Kulin NA, Pastuszak A, Sage SR, Schick-Boschetto B, Spivey G, Feldkamp M, Ormond K, Matsui D, Stein-Schechman AK, Cook L, Brochu J, Rieder M, Koren G. Pregnancy outcome following maternal use of the new selective serotonin reuptake inhibitors: a prospective controlled multicenter study. JAMA. 1998 Feb 25;279(8):609-10.</citation>
    <PMID>9486756</PMID>
  </reference>
  <reference>
    <citation>Beck CT. The effects of postpartum depression on child development: a meta-analysis. Arch Psychiatr Nurs. 1998 Feb;12(1):12-20.</citation>
    <PMID>9489170</PMID>
  </reference>
  <reference>
    <citation>Sinclair D, Murray L. Effects of postnatal depression on children's adjustment to school. Teacher's reports. Br J Psychiatry. 1998 Jan;172:58-63.</citation>
    <PMID>9534834</PMID>
  </reference>
  <reference>
    <citation>Weinberg MK, Tronick EZ. The impact of maternal psychiatric illness on infant development. J Clin Psychiatry. 1998;59 Suppl 2:53-61. Review.</citation>
    <PMID>9559760</PMID>
  </reference>
  <reference>
    <citation>Judd LL, Akiskal HS, Maser JD, Zeller PJ, Endicott J, Coryell W, Paulus MP, Kunovac JL, Leon AC, Mueller TI, Rice JA, Keller MB. A prospective 12-year study of subsyndromal and syndromal depressive symptoms in unipolar major depressive disorders. Arch Gen Psychiatry. 1998 Aug;55(8):694-700.</citation>
    <PMID>9707379</PMID>
  </reference>
  <reference>
    <citation>Teixeira JM, Fisk NM, Glover V. Association between maternal anxiety in pregnancy and increased uterine artery resistance index: cohort based study. BMJ. 1999 Jan 16;318(7177):153-7.</citation>
    <PMID>9888905</PMID>
  </reference>
  <reference>
    <citation>Ericson A, Källén B, Wiholm B. Delivery outcome after the use of antidepressants in early pregnancy. Eur J Clin Pharmacol. 1999 Sep;55(7):503-8.</citation>
    <PMID>10501819</PMID>
  </reference>
  <reference>
    <citation>Martins C, Gaffan EA. Effects of early maternal depression on patterns of infant-mother attachment: a meta-analytic investigation. J Child Psychol Psychiatry. 2000 Sep;41(6):737-46.</citation>
    <PMID>11039686</PMID>
  </reference>
  <reference>
    <citation>Cohen LS, Heller VL, Bailey JW, Grush L, Ablon JS, Bouffard SM. Birth outcomes following prenatal exposure to fluoxetine. Biol Psychiatry. 2000 Nov 15;48(10):996-1000.</citation>
    <PMID>11082474</PMID>
  </reference>
  <reference>
    <citation>Michaud CM, Murray CJ, Bloom BR. Burden of disease--implications for future research. JAMA. 2001 Feb 7;285(5):535-9.</citation>
    <PMID>11176854</PMID>
  </reference>
  <reference>
    <citation>Speer AM, Kimbrell TA, Wassermann EM, D Repella J, Willis MW, Herscovitch P, Post RM. Opposite effects of high and low frequency rTMS on regional brain activity in depressed patients. Biol Psychiatry. 2000 Dec 15;48(12):1133-41.</citation>
    <PMID>11137053</PMID>
  </reference>
  <reference>
    <citation>Uno H, Lohmiller L, Thieme C, Kemnitz JW, Engle MJ, Roecker EB, Farrell PM. Brain damage induced by prenatal exposure to dexamethasone in fetal rhesus macaques. I. Hippocampus. Brain Res Dev Brain Res. 1990 May 1;53(2):157-67.</citation>
    <PMID>2357788</PMID>
  </reference>
  <reference>
    <citation>Stiskal JA, Kulin N, Koren G, Ho T, Ito S. Neonatal paroxetine withdrawal syndrome. Arch Dis Child Fetal Neonatal Ed. 2001 Mar;84(2):F134-5.</citation>
    <PMID>11207233</PMID>
  </reference>
  <reference>
    <citation>Nordeng H, Lindemann R, Perminov KV, Reikvam A. Neonatal withdrawal syndrome after in utero exposure to selective serotonin reuptake inhibitors. Acta Paediatr. 2001 Mar;90(3):288-91.</citation>
    <PMID>11332169</PMID>
  </reference>
  <reference>
    <citation>Herwig U, Padberg F, Unger J, Spitzer M, Schönfeldt-Lecuona C. Transcranial magnetic stimulation in therapy studies: examination of the reliability of &quot;standard&quot; coil positioning by neuronavigation. Biol Psychiatry. 2001 Jul 1;50(1):58-61.</citation>
    <PMID>11457424</PMID>
  </reference>
  <reference>
    <citation>Hasey G. Transcranial magnetic stimulation in the treatment of mood disorder: a review and comparison with electroconvulsive therapy. Can J Psychiatry. 2001 Oct;46(8):720-7. Review.</citation>
    <PMID>11692974</PMID>
  </reference>
  <reference>
    <citation>Oberlander TF, Eckstein Grunau R, Fitzgerald C, Ellwood AL, Misri S, Rurak D, Riggs KW. Prolonged prenatal psychotropic medication exposure alters neonatal acute pain response. Pediatr Res. 2002 Apr;51(4):443-53.</citation>
    <PMID>11919328</PMID>
  </reference>
  <reference>
    <citation>Kelly RH, Russo J, Holt VL, Danielsen BH, Zatzick DF, Walker E, Katon W. Psychiatric and substance use disorders as risk factors for low birth weight and preterm delivery. Obstet Gynecol. 2002 Aug;100(2):297-304.</citation>
    <PMID>12151153</PMID>
  </reference>
  <reference>
    <citation>Sharma V. Pharmacotherapy of postpartum depression. Expert Opin Pharmacother. 2002 Oct;3(10):1421-31. Review.</citation>
    <PMID>12387688</PMID>
  </reference>
  <reference>
    <citation>Nulman I, Rovet J, Stewart DE, Wolpin J, Pace-Asciak P, Shuhaiber S, Koren G. Child development following exposure to tricyclic antidepressants or fluoxetine throughout fetal life: a prospective, controlled study. Am J Psychiatry. 2002 Nov;159(11):1889-95.</citation>
    <PMID>12411224</PMID>
  </reference>
  <reference>
    <citation>Costei AM, Kozer E, Ho T, Ito S, Koren G. Perinatal outcome following third trimester exposure to paroxetine. Arch Pediatr Adolesc Med. 2002 Nov;156(11):1129-32.</citation>
    <PMID>12413342</PMID>
  </reference>
  <reference>
    <citation>Simon GE, Cunningham ML, Davis RL. Outcomes of prenatal antidepressant exposure. Am J Psychiatry. 2002 Dec;159(12):2055-61.</citation>
    <PMID>12450956</PMID>
  </reference>
  <reference>
    <citation>Nitsche MA. Transcranial direct current stimulation: a new treatment for depression? Bipolar Disord. 2002;4 Suppl 1:98-9.</citation>
    <PMID>12479691</PMID>
  </reference>
  <reference>
    <citation>Hammen C, Brennan PA. Severity, chronicity, and timing of maternal depression and risk for adolescent offspring diagnoses in a community sample. Arch Gen Psychiatry. 2003 Mar;60(3):253-8.</citation>
    <PMID>12622658</PMID>
  </reference>
  <reference>
    <citation>Dennis CL. The effect of peer support on postpartum depression: a pilot randomized controlled trial. Can J Psychiatry. 2003 Mar;48(2):115-24.</citation>
    <PMID>12655910</PMID>
  </reference>
  <reference>
    <citation>Casper RC, Fleisher BE, Lee-Ancajas JC, Gilles A, Gaylor E, DeBattista A, Hoyme HE. Follow-up of children of depressed mothers exposed or not exposed to antidepressant drugs during pregnancy. J Pediatr. 2003 Apr;142(4):402-8.</citation>
    <PMID>12712058</PMID>
  </reference>
  <reference>
    <citation>Laine K, Heikkinen T, Ekblad U, Kero P. Effects of exposure to selective serotonin reuptake inhibitors during pregnancy on serotonergic symptoms in newborns and cord blood monoamine and prolactin concentrations. Arch Gen Psychiatry. 2003 Jul;60(7):720-6.</citation>
    <PMID>12860776</PMID>
  </reference>
  <reference>
    <citation>Fitzgerald PB, Brown TL, Marston NA, Daskalakis ZJ, De Castella A, Kulkarni J. Transcranial magnetic stimulation in the treatment of depression: a double-blind, placebo-controlled trial. Arch Gen Psychiatry. 2003 Oct;60(10):1002-8.</citation>
    <PMID>14557145</PMID>
  </reference>
  <reference>
    <citation>Nitsche MA, Liebetanz D, Lang N, Antal A, Tergau F, Paulus W. Safety criteria for transcranial direct current stimulation (tDCS) in humans. Clin Neurophysiol. 2003 Nov;114(11):2220-2; author reply 2222-3.</citation>
    <PMID>14580622</PMID>
  </reference>
  <reference>
    <citation>Gjerdingen D. The effectiveness of various postpartum depression treatments and the impact of antidepressant drugs on nursing infants. J Am Board Fam Pract. 2003 Sep-Oct;16(5):372-82. Review.</citation>
    <PMID>14645327</PMID>
  </reference>
  <reference>
    <citation>Lang N, Nitsche MA, Paulus W, Rothwell JC, Lemon RN. Effects of transcranial direct current stimulation over the human motor cortex on corticospinal and transcallosal excitability. Exp Brain Res. 2004 Jun;156(4):439-43. Epub 2004 Jan 24.</citation>
    <PMID>14745467</PMID>
  </reference>
  <reference>
    <citation>Bennett HA, Einarson A, Taddio A, Koren G, Einarson TR. Prevalence of depression during pregnancy: systematic review. Obstet Gynecol. 2004 Apr;103(4):698-709. Review. Erratum in: Obstet Gynecol. 2004 Jun;103(6):1344.</citation>
    <PMID>15051562</PMID>
  </reference>
  <reference>
    <citation>Dennis CL. Preventing postpartum depression part I: a review of biological interventions. Can J Psychiatry. 2004 Jul;49(7):467-75. Review.</citation>
    <PMID>15362251</PMID>
  </reference>
  <reference>
    <citation>Dennis CL, Stewart DE. Treatment of postpartum depression, part 1: a critical review of biological interventions. J Clin Psychiatry. 2004 Sep;65(9):1242-51. Review.</citation>
    <PMID>15367053</PMID>
  </reference>
  <reference>
    <citation>Dennis CL. Treatment of postpartum depression, part 2: a critical review of nonbiological interventions. J Clin Psychiatry. 2004 Sep;65(9):1252-65. Review.</citation>
    <PMID>15367054</PMID>
  </reference>
  <reference>
    <citation>Dennis CL. Preventing postpartum depression part II: A critical review of nonbiological interventions. Can J Psychiatry. 2004 Aug;49(8):526-38. Review. Erratum in: Can J Psychiatry. 2004 Oct;49(10):712.</citation>
    <PMID>15453102</PMID>
  </reference>
  <reference>
    <citation>Fitzgerald PB, Brown TL, Marston NA, Daskalakis ZJ, de Castella A, Bradshaw JL, Kulkarni J. Motor cortical excitability and clinical response to rTMS in depression. J Affect Disord. 2004 Oct 1;82(1):71-6.</citation>
    <PMID>15465578</PMID>
  </reference>
  <reference>
    <citation>DiPietro JA, Ghera MM, Costigan K, Hawkins M. Measuring the ups and downs of pregnancy stress. J Psychosom Obstet Gynaecol. 2004 Sep-Dec;25(3-4):189-201.</citation>
    <PMID>15715018</PMID>
  </reference>
  <reference>
    <citation>Fregni F, Boggio PS, Nitsche M, Bermpohl F, Antal A, Feredoes E, Marcolin MA, Rigonatti SP, Silva MT, Paulus W, Pascual-Leone A. Anodal transcranial direct current stimulation of prefrontal cortex enhances working memory. Exp Brain Res. 2005 Sep;166(1):23-30. Epub 2005 Jul 6.</citation>
    <PMID>15999258</PMID>
  </reference>
  <reference>
    <citation>Ardolino G, Bossi B, Barbieri S, Priori A. Non-synaptic mechanisms underlie the after-effects of cathodal transcutaneous direct current stimulation of the human brain. J Physiol. 2005 Oct 15;568(Pt 2):653-63. Epub 2005 Jul 21.</citation>
    <PMID>16037080</PMID>
  </reference>
  <reference>
    <citation>Fregni F, Boggio PS, Mansur CG, Wagner T, Ferreira MJ, Lima MC, Rigonatti SP, Marcolin MA, Freedman SD, Nitsche MA, Pascual-Leone A. Transcranial direct current stimulation of the unaffected hemisphere in stroke patients. Neuroreport. 2005 Sep 28;16(14):1551-5.</citation>
    <PMID>16148743</PMID>
  </reference>
  <reference>
    <citation>Pilowsky DJ, Wickramaratne PJ, Rush AJ, Hughes CW, Garber J, Malloy E, King CA, Cerda G, Sood AB, Alpert JE, Wisniewski SR, Trivedi MH, Talati A, Carlson MM, Liu HH, Fava M, Weissman MM. Children of currently depressed mothers: a STAR*D ancillary study. J Clin Psychiatry. 2006 Jan;67(1):126-36.</citation>
    <PMID>16426099</PMID>
  </reference>
  <reference>
    <citation>Cohen LS, Altshuler LL, Harlow BL, Nonacs R, Newport DJ, Viguera AC, Suri R, Burt VK, Hendrick V, Reminick AM, Loughead A, Vitonis AF, Stowe ZN. Relapse of major depression during pregnancy in women who maintain or discontinue antidepressant treatment. JAMA. 2006 Feb 1;295(5):499-507. Erratum in: JAMA. 2006 Jul 12;296(2):170.</citation>
    <PMID>16449615</PMID>
  </reference>
  <reference>
    <citation>Levinson-Castiel R, Merlob P, Linder N, Sirota L, Klinger G. Neonatal abstinence syndrome after in utero exposure to selective serotonin reuptake inhibitors in term infants. Arch Pediatr Adolesc Med. 2006 Feb;160(2):173-6.</citation>
    <PMID>16461873</PMID>
  </reference>
  <reference>
    <citation>Chambers CD, Hernandez-Diaz S, Van Marter LJ, Werler MM, Louik C, Jones KL, Mitchell AA. Selective serotonin-reuptake inhibitors and risk of persistent pulmonary hypertension of the newborn. N Engl J Med. 2006 Feb 9;354(6):579-87.</citation>
    <PMID>16467545</PMID>
  </reference>
  <reference>
    <citation>Fregni F, Boggio PS, Nitsche MA, Marcolin MA, Rigonatti SP, Pascual-Leone A. Treatment of major depression with transcranial direct current stimulation. Bipolar Disord. 2006 Apr;8(2):203-4.</citation>
    <PMID>16542193</PMID>
  </reference>
  <reference>
    <citation>Weissman MM, Pilowsky DJ, Wickramaratne PJ, Talati A, Wisniewski SR, Fava M, Hughes CW, Garber J, Malloy E, King CA, Cerda G, Sood AB, Alpert JE, Trivedi MH, Rush AJ; STAR*D-Child Team. Remissions in maternal depression and child psychopathology: a STAR*D-child report. JAMA. 2006 Mar 22;295(12):1389-98. Erratum in: JAMA. 2006 Sep 13;296(10):1234.</citation>
    <PMID>16551710</PMID>
  </reference>
  <reference>
    <citation>Fregni F, Boggio PS, Lima MC, Ferreira MJ, Wagner T, Rigonatti SP, Castro AW, Souza DR, Riberto M, Freedman SD, Nitsche MA, Pascual-Leone A. A sham-controlled, phase II trial of transcranial direct current stimulation for the treatment of central pain in traumatic spinal cord injury. Pain. 2006 May;122(1-2):197-209. Epub 2006 Mar 27.</citation>
    <PMID>16564618</PMID>
  </reference>
  <reference>
    <citation>Wen SW, Yang Q, Garner P, Fraser W, Olatunbosun O, Nimrod C, Walker M. Selective serotonin reuptake inhibitors and adverse pregnancy outcomes. Am J Obstet Gynecol. 2006 Apr;194(4):961-6.</citation>
    <PMID>16580283</PMID>
  </reference>
  <reference>
    <citation>Miranda PC, Lomarev M, Hallett M. Modeling the current distribution during transcranial direct current stimulation. Clin Neurophysiol. 2006 Jul;117(7):1623-9. Epub 2006 Jun 9.</citation>
    <PMID>16762592</PMID>
  </reference>
  <reference>
    <citation>Boggio PS, Castro LO, Savagim EA, Braite R, Cruz VC, Rocha RR, Rigonatti SP, Silva MT, Fregni F. Enhancement of non-dominant hand motor function by anodal transcranial direct current stimulation. Neurosci Lett. 2006 Aug 14;404(1-2):232-6. Epub 2006 Jun 30.</citation>
    <PMID>16808997</PMID>
  </reference>
  <reference>
    <citation>Fitzgerald PB, Benitez J, de Castella AR, Brown TL, Daskalakis ZJ, Kulkarni J. Naturalistic study of the use of transcranial magnetic stimulation in the treatment of depressive relapse. Aust N Z J Psychiatry. 2006 Sep;40(9):764-8.</citation>
    <PMID>16911751</PMID>
  </reference>
  <reference>
    <citation>Poreisz C, Boros K, Antal A, Paulus W. Safety aspects of transcranial direct current stimulation concerning healthy subjects and patients. Brain Res Bull. 2007 May 30;72(4-6):208-14. Epub 2007 Jan 24.</citation>
    <PMID>17452283</PMID>
  </reference>
  <reference>
    <citation>Loo CK, McFarquhar TF, Mitchell PB. A review of the safety of repetitive transcranial magnetic stimulation as a clinical treatment for depression. Int J Neuropsychopharmacol. 2008 Feb;11(1):131-47. Epub 2007 Sep 20. Review.</citation>
    <PMID>17880752</PMID>
  </reference>
  <reference>
    <citation>Marcus SM, Flynn HA. Depression, antidepressant medication, and functioning outcomes among pregnant women. Int J Gynaecol Obstet. 2008 Mar;100(3):248-51. Epub 2007 Nov 19.</citation>
    <PMID>18005968</PMID>
  </reference>
  <reference>
    <citation>Pilowsky DJ, Wickramaratne P, Talati A, Tang M, Hughes CW, Garber J, Malloy E, King C, Cerda G, Sood AB, Alpert JE, Trivedi MH, Fava M, Rush AJ, Wisniewski S, Weissman MM. Children of depressed mothers 1 year after the initiation of maternal treatment: findings from the STAR*D-Child Study. Am J Psychiatry. 2008 Sep;165(9):1136-47. doi: 10.1176/appi.ajp.2008.07081286. Epub 2008 Jun 16.</citation>
    <PMID>18558646</PMID>
  </reference>
  <reference>
    <citation>Flynn HA, Chermack ST. Prenatal alcohol use: the role of lifetime problems with alcohol, drugs, depression, and violence. J Stud Alcohol Drugs. 2008 Jul;69(4):500-9.</citation>
    <PMID>18612565</PMID>
  </reference>
  <reference>
    <citation>Dennis CL, Allen K. Interventions (other than pharmacological, psychosocial or psychological) for treating antenatal depression. Cochrane Database Syst Rev. 2008 Oct 8;(4):CD006795. doi: 10.1002/14651858.CD006795.pub2. Review. Update in: Cochrane Database Syst Rev. 2013;7:CD006795.</citation>
    <PMID>18843730</PMID>
  </reference>
  <reference>
    <citation>Anderson EL, Reti IM. ECT in pregnancy: a review of the literature from 1941 to 2007. Psychosom Med. 2009 Feb;71(2):235-42. doi: 10.1097/PSY.0b013e318190d7ca. Epub 2008 Dec 10. Review.</citation>
    <PMID>19073751</PMID>
  </reference>
  <reference>
    <citation>Fitzgerald PB, Hoy K, McQueen S, Maller JJ, Herring S, Segrave R, Bailey M, Been G, Kulkarni J, Daskalakis ZJ. A randomized trial of rTMS targeted with MRI based neuro-navigation in treatment-resistant depression. Neuropsychopharmacology. 2009 Apr;34(5):1255-62. doi: 10.1038/npp.2008.233. Epub 2009 Jan 14.</citation>
    <PMID>19145228</PMID>
  </reference>
  <reference>
    <citation>Marcus SM. Depression during pregnancy: rates, risks and consequences--Motherisk Update 2008. Can J Clin Pharmacol. 2009 Winter;16(1):e15-22. Epub 2009 Jan 22. Review.</citation>
    <PMID>19164843</PMID>
  </reference>
  <reference>
    <citation>Wisner KL, Sit DK, Hanusa BH, Moses-Kolko EL, Bogen DL, Hunker DF, Perel JM, Jones-Ivy S, Bodnar LM, Singer LT. Major depression and antidepressant treatment: impact on pregnancy and neonatal outcomes. Am J Psychiatry. 2009 May;166(5):557-66. doi: 10.1176/appi.ajp.2008.08081170. Epub 2009 Mar 16.</citation>
    <PMID>19289451</PMID>
  </reference>
  <reference>
    <citation>Gibson J, McKenzie-McHarg K, Shakespeare J, Price J, Gray R. A systematic review of studies validating the Edinburgh Postnatal Depression Scale in antepartum and postpartum women. Acta Psychiatr Scand. 2009 May;119(5):350-64. doi: 10.1111/j.1600-0447.2009.01363.x. Epub 2009 Mar 2. Review.</citation>
    <PMID>19298573</PMID>
  </reference>
  <reference>
    <citation>Nitsche MA, Boggio PS, Fregni F, Pascual-Leone A. Treatment of depression with transcranial direct current stimulation (tDCS): a review. Exp Neurol. 2009 Sep;219(1):14-9. doi: 10.1016/j.expneurol.2009.03.038. Epub 2009 Apr 5. Review.</citation>
    <PMID>19348793</PMID>
  </reference>
  <reference>
    <citation>Merzagora AC, Foffani G, Panyavin I, Mordillo-Mateos L, Aguilar J, Onaral B, Oliviero A. Prefrontal hemodynamic changes produced by anodal direct current stimulation. Neuroimage. 2010 Feb 1;49(3):2304-10. doi: 10.1016/j.neuroimage.2009.10.044. Epub 2009 Oct 21.</citation>
    <PMID>19853048</PMID>
  </reference>
  <reference>
    <citation>Oberlander TF, Gingrich JA, Ansorge MS. Sustained neurobehavioral effects of exposure to SSRI antidepressants during development: molecular to clinical evidence. Clin Pharmacol Ther. 2009 Dec;86(6):672-7. doi: 10.1038/clpt.2009.201. Epub 2009 Nov 4.</citation>
    <PMID>19890255</PMID>
  </reference>
  <reference>
    <citation>Dennis CL. Postpartum depression peer support: maternal perceptions from a randomized controlled trial. Int J Nurs Stud. 2010 May;47(5):560-8. doi: 10.1016/j.ijnurstu.2009.10.015. Epub 2009 Dec 4.</citation>
    <PMID>19962699</PMID>
  </reference>
  <reference>
    <citation>You JJ, Alter DA, Stukel TA, McDonald SD, Laupacis A, Liu Y, Ray JG. Proliferation of prenatal ultrasonography. CMAJ. 2010 Feb 9;182(2):143-51. doi: 10.1503/cmaj.090979. Epub 2010 Jan 4.</citation>
    <PMID>20048009</PMID>
  </reference>
  <reference>
    <citation>Vigod SN, Villegas L, Dennis CL, Ross LE. Prevalence and risk factors for postpartum depression among women with preterm and low-birth-weight infants: a systematic review. BJOG. 2010 Apr;117(5):540-50. doi: 10.1111/j.1471-0528.2009.02493.x. Epub 2010 Jan 29. Review.</citation>
    <PMID>20121831</PMID>
  </reference>
  <reference>
    <citation>Ross LE, McQueen K, Vigod S, Dennis CL. Risk for postpartum depression associated with assisted reproductive technologies and multiple births: a systematic review. Hum Reprod Update. 2011 Jan-Feb;17(1):96-106. doi: 10.1093/humupd/dmq025. Epub 2010 Jul 6. Review.</citation>
    <PMID>20605900</PMID>
  </reference>
  <reference>
    <citation>Ray JG, Schull MJ, Urquia ML, You JJ, Guttmann A, Vermeulen MJ. Major radiodiagnostic imaging in pregnancy and the risk of childhood malignancy: a population-based cohort study in Ontario. PLoS Med. 2010 Sep 7;7(9):e1000337. doi: 10.1371/journal.pmed.1000337.</citation>
    <PMID>20838660</PMID>
  </reference>
  <reference>
    <citation>Brunoni AR, Valiengo L, Baccaro A, Zanao TA, de Oliveira JF, Vieira GP, Bueno VF, Goulart AC, Boggio PS, Lotufo PA, Bensenor IM, Fregni F. Sertraline vs. ELectrical Current Therapy for Treating Depression Clinical Trial--SELECT TDCS: design, rationale and objectives. Contemp Clin Trials. 2011 Jan;32(1):90-8. doi: 10.1016/j.cct.2010.09.007. Epub 2010 Sep 18.</citation>
    <PMID>20854930</PMID>
  </reference>
  <reference>
    <citation>Wickramaratne P, Gameroff MJ, Pilowsky DJ, Hughes CW, Garber J, Malloy E, King C, Cerda G, Sood AB, Alpert JE, Trivedi MH, Fava M, Rush AJ, Wisniewski S, Weissman MM. Children of depressed mothers 1 year after remission of maternal depression: findings from the STAR*D-Child study. Am J Psychiatry. 2011 Jun;168(6):593-602. doi: 10.1176/appi.ajp.2010.10010032. Epub 2011 Mar 15.</citation>
    <PMID>21406462</PMID>
  </reference>
  <reference>
    <citation>Yonkers KA, Vigod S, Ross LE. Diagnosis, pathophysiology, and management of mood disorders in pregnant and postpartum women. Obstet Gynecol. 2011 Apr;117(4):961-77. doi: 10.1097/AOG.0b013e31821187a7. Review.</citation>
    <PMID>21422871</PMID>
  </reference>
  <reference>
    <citation>Rurak D, Lim K, Sanders A, Brain U, Riggs W, Oberlander TF. Third trimester fetal heart rate and Doppler middle cerebral artery blood flow velocity characteristics during prenatal selective serotonin reuptake inhibitor exposure. Pediatr Res. 2011 Jul;70(1):96-101. doi: 10.1203/PDR.0b013e31821ba11a.</citation>
    <PMID>21436759</PMID>
  </reference>
  <reference>
    <citation>Mulder EJ, Ververs FF, de Heus R, Visser GH. Selective serotonin reuptake inhibitors affect neurobehavioral development in the human fetus. Neuropsychopharmacology. 2011 Sep;36(10):1961-71. doi: 10.1038/npp.2011.67. Epub 2011 Apr 27.</citation>
    <PMID>21525859</PMID>
  </reference>
  <reference>
    <citation>Blumberger DM, Mulsant BH, Fitzgerald PB, Rajji TK, Ravindran AV, Young LT, Levinson AJ, Daskalakis ZJ. A randomized double-blind sham-controlled comparison of unilateral and bilateral repetitive transcranial magnetic stimulation for treatment-resistant major depression. World J Biol Psychiatry. 2012 Sep;13(6):423-35. doi: 10.3109/15622975.2011.579163. Epub 2011 Jul 8.</citation>
    <PMID>21736507</PMID>
  </reference>
  <reference>
    <citation>Raimundo RJ, Uribe CE, Brasil-Neto JP. Lack of clinically detectable acute changes on autonomic or thermoregulatory functions in healthy subjects after transcranial direct current stimulation (tDCS). Brain Stimul. 2012 Jul;5(3):196-200. doi: 10.1016/j.brs.2011.03.009. Epub 2011 Apr 27.</citation>
    <PMID>22037121</PMID>
  </reference>
  <reference>
    <citation>Loo CK, Alonzo A, Martin D, Mitchell PB, Galvez V, Sachdev P. Transcranial direct current stimulation for depression: 3-week, randomised, sham-controlled trial. Br J Psychiatry. 2012 Jan;200(1):52-9. doi: 10.1192/bjp.bp.111.097634.</citation>
    <PMID>22215866</PMID>
  </reference>
  <reference>
    <citation>Kalu UG, Sexton CE, Loo CK, Ebmeier KP. Transcranial direct current stimulation in the treatment of major depression: a meta-analysis. Psychol Med. 2012 Sep;42(9):1791-800. doi: 10.1017/S0033291711003059. Epub 2012 Jan 12. Review.</citation>
    <PMID>22236735</PMID>
  </reference>
  <reference>
    <citation>Blumberger DM, Christensen BK, Zipursky RB, Moller B, Chen R, Fitzgerald PB, Daskalakis ZJ. MRI-targeted repetitive transcranial magnetic stimulation of Heschl's gyrus for refractory auditory hallucinations. Brain Stimul. 2012 Oct;5(4):577-85. doi: 10.1016/j.brs.2011.12.002. Epub 2012 Feb 22.</citation>
    <PMID>22410480</PMID>
  </reference>
  <reference>
    <citation>Dennis CL, Ravitz P, Grigoriadis S, Jovellanos M, Hodnett E, Ross L, Zupancic J. The effect of telephone-based interpersonal psychotherapy for the treatment of postpartum depression: study protocol for a randomized controlled trial. Trials. 2012 Apr 19;13:38. doi: 10.1186/1745-6215-13-38.</citation>
    <PMID>22515528</PMID>
  </reference>
  <reference>
    <citation>Brunoni AR, Vanderhasselt MA, Boggio PS, Fregni F, Dantas EM, Mill JG, Lotufo PA, Benseñor IM. Polarity- and valence-dependent effects of prefrontal transcranial direct current stimulation on heart rate variability and salivary cortisol. Psychoneuroendocrinology. 2013 Jan;38(1):58-66. doi: 10.1016/j.psyneuen.2012.04.020. Epub 2012 May 22.</citation>
    <PMID>22626867</PMID>
  </reference>
  <reference>
    <citation>Fitzgerald PB, Grace N, Hoy KE, Bailey M, Daskalakis ZJ. An open label trial of clustered maintenance rTMS for patients with refractory depression. Brain Stimul. 2013 May;6(3):292-7. doi: 10.1016/j.brs.2012.05.003. Epub 2012 Jun 1.</citation>
    <PMID>22683273</PMID>
  </reference>
  <reference>
    <citation>Hanley GE, Oberlander TF. Neurodevelopmental outcomes following prenatal exposure to serotonin reuptake inhibitor antidepressants: a &quot;social teratogen&quot; or moderator of developmental risk? Birth Defects Res A Clin Mol Teratol. 2012 Aug;94(8):651-9. doi: 10.1002/bdra.23032. Epub 2012 Jun 26. Review.</citation>
    <PMID>22733632</PMID>
  </reference>
  <reference>
    <citation>Blumberger DM, Tran LC, Fitzgerald PB, Hoy KE, Daskalakis ZJ. A randomized double-blind sham-controlled study of transcranial direct current stimulation for treatment-resistant major depression. Front Psychiatry. 2012 Aug 17;3:74. doi: 10.3389/fpsyt.2012.00074. eCollection 2012.</citation>
    <PMID>22912618</PMID>
  </reference>
  <reference>
    <citation>Weikum WM, Oberlander TF, Hensch TK, Werker JF. Prenatal exposure to antidepressants and depressed maternal mood alter trajectory of infant speech perception. Proc Natl Acad Sci U S A. 2012 Oct 16;109 Suppl 2:17221-7. doi: 10.1073/pnas.1121263109. Epub 2012 Oct 8.</citation>
    <PMID>23045665</PMID>
  </reference>
  <reference>
    <citation>Dennis CL, Heaman M, Vigod S. Epidemiology of postpartum depressive symptoms among Canadian women: regional and national results from a cross-sectional survey. Can J Psychiatry. 2012 Sep;57(9):537-46.</citation>
    <PMID>23073031</PMID>
  </reference>
  <reference>
    <citation>Seitz DP, Vigod SN, Lin E, Gruneir A, Newman A, Anderson G, Rapoport MJ, Rochon P, Blumberger DM, Herrmann N. Characteristics of older adults hospitalized in acute psychiatric units in ontario: a population-based study. Can J Psychiatry. 2012 Sep;57(9):554-63.</citation>
    <PMID>23073033</PMID>
  </reference>
  <reference>
    <citation>Nulman I, Koren G, Rovet J, Barrera M, Pulver A, Streiner D, Feldman B. Neurodevelopment of children following prenatal exposure to venlafaxine, selective serotonin reuptake inhibitors, or untreated maternal depression. Am J Psychiatry. 2012 Nov;169(11):1165-74. doi: 10.1176/appi.ajp.2012.11111721.</citation>
    <PMID>23128923</PMID>
  </reference>
  <reference>
    <citation>Byatt N, Simas TA, Lundquist RS, Johnson JV, Ziedonis DM. Strategies for improving perinatal depression treatment in North American outpatient obstetric settings. J Psychosom Obstet Gynaecol. 2012 Dec;33(4):143-61. doi: 10.3109/0167482X.2012.728649. Review.</citation>
    <PMID>23194018</PMID>
  </reference>
  <reference>
    <citation>Dennis CL, Coghlan M, Vigod S. Can we identify mothers at-risk for postpartum anxiety in the immediate postpartum period using the State-Trait Anxiety Inventory? J Affect Disord. 2013 Sep 25;150(3):1217-20. doi: 10.1016/j.jad.2013.05.049. Epub 2013 Jun 10.</citation>
    <PMID>23764383</PMID>
  </reference>
  <reference>
    <citation>Kennedy SH, Lam RW, Cohen NL, Ravindran AV; CANMAT Depression Work Group. Clinical guidelines for the treatment of depressive disorders. IV. Medications and other biological treatments. Can J Psychiatry. 2001 Jun;46 Suppl 1:38S-58S. Review.</citation>
    <PMID>11441771</PMID>
  </reference>
  <reference>
    <citation>World Health Organization. (WHO). Guidelines for Good Clinical Practice (GCP) for Trials on Pharmaceutical Products. WHO Technical Report Series, No. 850. (1995). 97-137</citation>
  </reference>
  <reference>
    <citation>Bricker, D &amp; Squires, J. Ages and Stages Questionnaire. 3rd Ed. Baltimore, MD: Brookes Publishing; 2010.</citation>
  </reference>
  <reference>
    <citation>GlaxoSmithKline. GSK medicine: Bupropion and Paroxetine. Epidemiology study: Preliminary report on bupropion in pregnancy and the occurrence of cardiovascular and major congenital malformation (Study EPIP083). 2006; http://ctr.gsk.co.uk/summary/paroxetime/epip083.pdf.</citation>
  </reference>
  <reference>
    <citation>Vigod SN, Kurdyak PA, Dennis CL, Leszcz T, Taylor VH, Blumberger DM, Seitz DP. Transitional interventions to reduce early psychiatric readmissions in adults: systematic review. Br J Psychiatry. 2013 Mar;202(3):187-94. doi: 10.1192/bjp.bp.112.115030. Review.</citation>
    <PMID>23457182</PMID>
  </reference>
  <reference>
    <citation>Demissie, K, Jospeh, KS, Dzakpasu, S. Perinatal Health Indicators for Canada: A Resource Manual. Public Health Agency of Canda, Canadian Perinatal Surveillance System. 2000; Ottawa, ON.</citation>
  </reference>
  <reference>
    <citation>Zuckerman B, Amaro H, Bauchner H, Cabral H. Depressive symptoms during pregnancy: relationship to poor health behaviors. Am J Obstet Gynecol. 1989 May;160(5 Pt 1):1107-11.</citation>
    <PMID>2729387</PMID>
  </reference>
  <reference>
    <citation>O'Hara MW, Swain AM. Rates and risk of postpartum depression: A meta-analysis. International Review of Psychiatry. 1996;8(1):37-54.</citation>
  </reference>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 2, 2014</study_first_submitted>
  <study_first_submitted_qc>April 14, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 16, 2014</study_first_posted>
  <last_update_submitted>July 27, 2017</last_update_submitted>
  <last_update_submitted_qc>July 27, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 31, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Depression</keyword>
  <keyword>Pregnancy</keyword>
  <keyword>Transcranial Direct Current Stimulation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

